stockrowEton Pharmaceuticals, Inc.
ETON Healthcare Drug Manufacturers Specialty & Generic
Eton Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.0 million, up 104.9% from fiscal 2024.
- Revenue
- +157.9%
- EPS
- +1,857.1%
- Free cash flow
- +172.6%
- Total debt
- −24.0%
Quarter to September 2026, against a year earlier
Follow ETON
Alert me
Eton Pharmaceuticals, Inc. (ETON) P/E ratio
As of 5 November 2026, Eton Pharmaceuticals, Inc. (ETON) trades at a P/E ratio of 26.8×. Over the past ten years it has ranged from 0.0× (June 2026) to 137× (August 2026); the current reading is higher than 89% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 20.5× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 29.1× | (62.23%) |
| Jun 2026 | 77.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 25 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XERS Xeris Biopharma Holdings, Inc. compare | n/m |
| HROW Harrow, Inc. compare | n/m |
| ALVO Alvotech compare | n/m |
| AMPH Amphastar Pharmaceuticals, Inc. compare | 12.3× |
| ANIP ANI Pharmaceuticals, Inc. compare | 13.3× |
| PAHC Phibro Animal Health Corporation compare | 14.0× |
| CRON Cronos Group Inc. compare | 21.9× |
| ETON Eton Pharmaceuticals, Inc. | 26.8× |
| PCRX Pacira BioSciences, Inc. compare | 38.4× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)